Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours

Inclusion Criteria: * Age \>=18 years. * Histological or cytological documentation of non hematologic, malignant solid tumour. * Have failed at least one previous therapeutic regimen. * LIfe expectancy \>= 12 weeks. * ECOG performance status 0 or 1. * Written, signed and dated informed consent. * Able and willing to meet all protocol-required treatments, investigations and visits. * Have adequate organ function. Exclusion Criteria: * Clinically significant non-malignant disease. * Active CNS metastases. * Subjects with uncontrolled diabetes. * History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents * Concomitant use of aspirin (\> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose), heparin within two weeks prior to randomisation, or other anti-platelet drugs. * History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media. * Known seropositivity to the human immunodeficiency vies (HIV) * Women who are pregnant or breast feeding * Women of child-bearing potential and male subjects who are partners of women of child bearing potential who are unable or unwilling to use effective means of contraception. * Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.